Novel Coronavirus Updates – Two Videos & A Podcast
We’ve got two more videos regarding the novel coronavirus, as well as a podcast link, featuring an interview with Dr. Seheult and Garage Talk’s Mike Sheahan. Our 11th and 12th video updates cover Antiviral Drugs & Treatment Trials for nCoV (Remdesivir, Chloroquine) and Unsupported Theories, Pneumonia, ACE2 & nCoV.
Novel Coronavirus in the News
The number of infections, deaths, and recoveries continue to rise as more information is discovered and revealed about the novel coronavirus outbreak. In our 11th video on the subject, Dr. Seheult talks about increased access to testing in the U.S., as the CDC has begun distributing tests to local labs for processing.
Dr. Seheult also revisits the story of the Diamond Princess cruise ship with 3,700 people on board, currently floating off the coast of Japan. So far, one man who had been on the ship in late January has tested positive for novel coronavirus, and since this time, 10 more people who boarded the ship after him were also diagnosed with nCoV. It is unclear whether or not these cases are directly related.
Antiviral Drugs and Treatment Trials for nCoV
In this video, Dr. Seheult also talks about a letter to the editor posted in Nature. This letter discussed two FDA approved medications, Remdesivir and Chloroquine, and their efficaciousness of stunting the novel coronavirus in vitro, as well as in compassionate use cases. Although in vitro results have been promising, there have been no randomized, placebo-controlled trials. It’s predicted that we’ll know more on these and other research-backed nCoV medications by late April.
Unsupported Theories, Pneumonia, ACE-2 & nCoV
In our 12th update video, Dr. Seheult questions some unsubstantiated theories surrounding the novel coronavirus update, including one involving the Chinese company Tencent and alleged “leaked” numbers of confirmed diagnoses and deaths.
Additionally, he talks about a couple of preliminary/non-peer-reviewed papers on Angiotensin Converting Enzyme 2 (ACE-2), the receptor that allows internalization of nCoV, the novel coronavirus. Although we can’t make any assumptions based on these studies alone, they highlight further similarities between nCoV and SARs and show potential for further exploration of the role of ACE-2 in nCoV treatment.
Recap of MedCram’s nCoV Coverage
As always, continue following along for further updates on the novel coronavirus. Here are links to the videos and information we’ve produced so far:
- Coronavirus Outbreak, Transmission, and Pathophysiology
- Coronavirus Symptoms, Diagnosis, and Treatment
- Coronavirus Update 3: Spread, Quarantine, Projections, and Vaccine
- How Coronavirus Kills: Acute Respiratory Distress Syndrome (ARDS) & Treatment
- Coronavirus Epidemic Update 5: Mortality Rate vs SARS / Influenza
- Coronavirus Outbreak Update 6: Asymptomatic Transmission & Incubation Period
- Coronavirus Epidemic Update 7: Global Health Emergency Declared, Viral Shedding
- Coronavirus Outbreak Update 8: Travel Ban, Spread Outside of China, Quarantine, & MRSA
- Coronavirus Epidemic Update 9: Fecal-Oral Transmission, Recovery vs Death Rate
- Coronavirus Epidemic Update 10: New Studies, Transmission, Spread from Wuhan, Prevention (nocv 2019)
- Coronavirus Epidemic Update 11: Antiviral Drugs, Treatment Trials for nCoV (Remdesivir, Chloroquine)
- Coronavirus Epidemic Update 12: Unsupported Theories, Pneumonia, ACE2 & nCoV
- Garage Talk Podcast — Dr. Roger Seheult and the Coronavirus